XML 110 R93.htm IDEA: XBRL DOCUMENT v3.25.4
Supplemental equity and other information - Narrative (Details)
$ / shares in Units, shares in Thousands, $ in Millions
 12 Months Ended
Dec. 31, 2025
USD ($)
shares
$ / shares
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Stockholders Equity Note [Line Items]      
Share-based compensation cost | $ $ 9.1 $ 12.5 $ 16.6
Unrecognized compensation cost related to non-vested share-based compensation | $ $ 15.4    
Unrecognized compensation recognition period 2 years 2 months 12 days    
Number of stock options (in shares) | shares 4,716    
Weighted average grant date fair value (in dollars per shares) | $ / shares $ 0.86    
Weighted average exercise price (in dollars per share) | $ / shares $ 14.23    
Remaining contractual term (in years) 3 years 1 month 6 days    
RSA      
Stockholders Equity Note [Line Items]      
Vesting period (years) 3 years    
Aggregate intrinsic value of unvested | $ $ 5.7    
RSUs      
Stockholders Equity Note [Line Items]      
Vesting period (years) 3 years    
Aggregate intrinsic value of unvested | $ $ 21.6    
CPU's and LTCA's      
Stockholders Equity Note [Line Items]      
Vesting period (years) 3 years    
Unrecognized compensation expense | $ $ 14.9    
2027 Notes | Convertible Debt      
Stockholders Equity Note [Line Items]      
Aggregate shares receivable upon conversion (shares) | shares 14,300    
Securities excluded from computation of earnings per share (in shares) | shares 9,400    
2031 Notes | Convertible Debt      
Stockholders Equity Note [Line Items]      
Aggregate shares receivable upon conversion (shares) | shares 143,900    
Securities excluded from computation of earnings per share (in shares) | shares 99,100